832 related articles for article (PubMed ID: 12699392)
1. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
2. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
[TBL] [Abstract][Full Text] [Related]
3. Dichlorobis(2-phenylazopyridine)ruthenium(II) complexes: characterisation, spectroscopic and structural properties of four isomers.
Velders AH; van der Schilden K; Hotze AC; Reedijk J; Kooijman H; Spek AL
Dalton Trans; 2004 Feb; (3):448-55. PubMed ID: 15252553
[TBL] [Abstract][Full Text] [Related]
4. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
5. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
7. Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2].
Hotze AC; Caspers SE; de Vos D; Kooijman H; Spek AL; Flamigni A; Bacac M; Sava G; Haasnoot JG; Reedijk J
J Biol Inorg Chem; 2004 Apr; 9(3):354-64. PubMed ID: 15034769
[TBL] [Abstract][Full Text] [Related]
8. New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin.
Komeda S; Kalayda GV; Lutz M; Spek AL; Yamanaka Y; Sato T; Chikuma M; Reedijk J
J Med Chem; 2003 Mar; 46(7):1210-9. PubMed ID: 12646031
[TBL] [Abstract][Full Text] [Related]
9. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
[TBL] [Abstract][Full Text] [Related]
10. 1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity.
Bratsos I; Urankar D; Zangrando E; Genova-Kalou P; Košmrlj J; Alessio E; Turel I
Dalton Trans; 2011 May; 40(19):5188-99. PubMed ID: 21465046
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and assessment of the cytotoxic properties of cis and trans-[Pd(L)(2)Cl(2)] complexes involving 6-benzylamino-9-isopropylpurine derivatives.
Trávnícek Z; Szucová L; Popa I
J Inorg Biochem; 2007 Mar; 101(3):477-92. PubMed ID: 17208304
[TBL] [Abstract][Full Text] [Related]
12. Ligands rock & roll: stepwise twisting of two cis-coordinated lopsided N-heterocycles in an octahedral bis(2-phenylazopyridine)-ruthenium(II) complex with seven atropisomers.
Velders AH; Hotze AC; Reedijk J
Chemistry; 2005 Feb; 11(4):1325-40. PubMed ID: 15643666
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
14. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
15. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, crystal structure, studies in solution and cytotoxicity of two new fluorescent platinum(II) compounds containing anthracene derivatives as a carrier ligand.
Marqués-Gallego P; den Dulk H; Brouwer J; Kooijman H; Spek AL; Roubeau O; Teat SJ; Reedijk J
Inorg Chem; 2008 Dec; 47(23):11171-9. PubMed ID: 18975941
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand.
Marzano C; Pellei M; Colavito D; Alidori S; Lobbia GG; Gandin V; Tisato F; Santini C
J Med Chem; 2006 Dec; 49(25):7317-24. PubMed ID: 17149861
[TBL] [Abstract][Full Text] [Related]
19. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
20. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.
Vock CA; Ang WH; Scolaro C; Phillips AD; Lagopoulos L; Juillerat-Jeanneret L; Sava G; Scopelliti R; Dyson PJ
J Med Chem; 2007 May; 50(9):2166-75. PubMed ID: 17419606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
